Logo

AdvanDx Pockets $15M in Series C Funds; Will Use Cash to Drive S&M, R&D

Sep 19, 2007
NEW YORK (GenomeWeb News) — Molecular diagnostics developer AdvanDx will use a $15 million blast of Series C financing from BioMérieux and two existing investors to push sales and marketing efforts and to expand its R&D facilities, the company said yesterday.
 
Joining BioMérieux in the financing is LD Pensions and Scandinavian Life Science Venture.
 
AdvanDx makes a suite of diagnostics for detecting, identifying, and managing pathogens and infections, including the PNA FISH and Evigene tests, which detect antibiotic-resistant bacteria.
 
BioMérieux in May become Advent’s US distributor of tests for identifying Staphylococcus aureus, Candida albicans, and Enterococcus faecalis.
Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.